Related Experiment Videos

A UK Healthcare Professional Perspective on the Implementation of Monitoring in Children and Young People With

Rabbi Swaby1, Julia Townson2, Rachel E J Besser1,3

  • 1Diabetes and Inflammation Laboratory, Centre for Human Genetics, Nuffield Department of Medicine, Bukhman Centre for Research Excellence in Type 1 Diabetes, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Diabetes, Obesity & Metabolism
|July 26, 2026
PubMed

Insights

Healthcare professionals (HCPs) support monitoring children and young people (CYP) with early-stage type 1 diabetes (T1D). However, they need clear guidance, training, and expanded services for successful clinical implementation.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Clinical Practice Research

Background:

  • Screening and monitoring of children and young people (CYP) with early-stage type 1 diabetes (T1D) is increasing.
  • Healthcare professionals' (HCPs) perspectives on implementing these monitoring strategies in clinical practice are not well understood.

Purpose of the Study:

  • To explore UK-based HCPs' views on monitoring CYP with early-stage T1D within clinical care.
  • To identify potential barriers and facilitators for implementing monitoring strategies.

Main Methods:

  • Semi-structured interviews were conducted with 15 HCPs from UK pediatric diabetes multidisciplinary teams.
  • Thematic analysis was used to analyze data on HCPs' perspectives regarding monitoring CYP for T1D progression.

Main Results:

  • Three key themes emerged: uncertainty in managing early-stage T1D, the need for guidance and consistent messaging, and challenges in integrating monitoring into clinical care.
  • HCPs expressed a need for knowledge and clear pathways for risk assessment, monitoring test selection, and family communication.
  • Support for monitoring was evident, but participants stressed the necessity of expanding clinical services and upskilling the workforce.

Conclusions:

  • HCPs are willing to support T1D monitoring in CYP within clinical settings.
  • Key barriers to national implementation include the need for enhanced HCP education, standardized national guidance, and expanded clinical services.
Abstract

Keywords:
early‐stagemanagementmonitoringstagingtype 1 diabetes

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...